Company Description

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.

The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.

It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers.

Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Polyrizon Ltd.

Country	Israel
Founded	2005
IPO Date	Oct 29, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Tomer Izraeli

Contact Details

Address: 5 Ha-Tidhar Street Ra'anana, 4366507 Israel
Phone	972 9 374 0120
Website	polyrizon-biotech.com

Stock Details

Ticker Symbol	PLRZ
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.38
CIK Code	0001893645
CUSIP Number	M79549107
ISIN Number	IL0011814113
SIC Code	3841

Key Executives

Name	Position
Tomer Izraeli	Founder, Chief Executive Officer and Director
Nir Ben Yosef	Chief Financial Officer and Compliance Officer
Dr. Tidhar Turgeman	Chief Technology Officer
Dr. Eyal S. Ron Ph.D.	Chief Scientific Officer
Daphna Avital	Chief People Officer

Latest SEC Filings

Date	Type	Title
May 12, 2025	EFFECT	Notice of Effectiveness
May 12, 2025	424B3	Prospectus
May 1, 2025	6-K	Report of foreign issuer
May 1, 2025	6-K	Report of foreign issuer
Apr 30, 2025	F-1	Registration statement for certain foreign private issuers
Apr 25, 2025	6-K	Report of foreign issuer
Apr 17, 2025	6-K	Report of foreign issuer
Apr 11, 2025	6-K	Report of foreign issuer
Apr 2, 2025	6-K	Report of foreign issuer
Apr 1, 2025	6-K	Report of foreign issuer

View All SEC Filings